Sudeep Pharma Ltd

Sudeep Pharma Earnings Call Transcript: Key Takeaways

Sudeep Pharma delivered record quarterly revenue led by its Pharma Food Nutrition (PFN) segment, though specialty ingredients face short-term headwinds from the pause of a government rice program.

Sudeep Pharma Investor Presentation: Key Takeaways

Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.

Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY

Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.

Key figure

Net profit ₹51.8 Cr · +10.7% YoY

Sudeep Pharma Capacity Expansion

Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.

manufacturing capacity

51200 MT

Sudeep Pharma Board Meeting Date

Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.